Intravitreal bevacizumab (Avastin) versus triamcinolone (Volon A) for treatment of diabetic macular edema: one-year results

Eye (Basingstoke)

Volumn 28, Issue 1, 2014, Pages 10-16

  Kriechbaum, K ^a   Prager, S ^a   Mylonas, G ^a   Scholda, C ^a   Rainer, G ^a   Funk, M ^a   Kundi, M ^a   Schmidt Erfurth, U ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

bevacizumab; diabetic macular edema; triamcinolone

Indexed keywords

BEVACIZUMAB; TRIAMCINOLONE ACETONIDE; ANGIOGENESIS INHIBITOR; GLUCOCORTICOID; MONOCLONAL ANTIBODY; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; ARTICLE; CATARACT; CENTRAL RETINAL THICKNESS; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; DIABETIC PATIENT; ENDOPHTHALMITIS; FEMALE; HUMAN; MALE; MIDDLE AGED; MORPHOLOGY; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RETREATMENT; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; VISUAL ACUITY; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DIABETIC RETINOPATHY; DRUG ANTAGONISM; INTRAVITREAL DRUG ADMINISTRATION; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; RETINA; RETINA MACULA EDEMA; TREATMENT OUTCOME;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; DIABETIC RETINOPATHY; FEMALE; GLUCOCORTICOIDS; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RETINA; TREATMENT OUTCOME; TRIAMCINOLONE ACETONIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84891934597     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2013.242     Document Type: Article

References (19)

1. Rogers SL, Tikellis G, Cheung N, Tapp R, Shaw J, Zimmet PZ et al. Retinal arteriolar caliber predicts incident retinopathy: The Australian Diabetes, Obesity and Lifestyle (AusDiab) study. Diabetes Care 2008; 31(4): 761-763
2. Focal photocoagulation treatment of diabetic macular edema. Relationship of treatment effect to fluorescein angiographic and other retinal characteristics at baseline: ETDRS report no. 19. Early Treatment Diabetic Retinopathy Study Research Group. Arch Ophthalmol 1995; 113(9): 1144-1155
3. Noma H, Funatsu H, Yamasaki M, Tsukamoto H, Mimura T, Sone T et al. Pathogenesis of macular edema with branch retinal vein occlusion and intraocular levels of vascular endothelial growth factor and interleukin-6. Am J Ophthalmol 2005; 140(2): 256-261
4. Jaissle GB, Szurman P, Bartz-Schmidt KU. [Recommendation for the implementation of intravitreal injections-statement of the German Retina Society, the German Society of Ophthalmology (DOG) and the German Professional Association of Ophthalmologists (BVA)]. Klin Monbl Augenheilkd 2005; 222(5): 390-395
5. Klein R, Moss SE, Klein BE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. XI. The incidence of macular edema. Ophthalmology 1989; 96(10): 1501-1510
6. Patel JI, Tombran-Tink J, Hykin PG, Gregor ZJ, Cree IA. Vitreous and aqueous concentrations of proangiogenic, antiangiogenic factors and other cytokines in diabetic retinopathy patients with macular edema: Implications for structural differences in macular profiles. Exp Eye Res 2006; 82(5): 798-806
7. Shimura M, Nakazawa T, Yasuda K, Shiono T, Iida T, Sakamoto T et al. Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema. Am J Ophthalmol 2008; 145(5): 854-861
8. Techniques for scatter and local photocoagulation treatment of diabetic retinopathy: Early Treatment Diabetic Retinopathy Study Report no. 3. The Early Treatment Diabetic Retinopathy Study Research Group. Int Ophthalmol Clin 1987; 27(4): 254-264
9. Massin P, Bandello F, Garweg JG, Hansen LL, Harding SP, Larsen M et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): A 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care 2010; 33(11): 2399-2405
10. Mitchell P, Bandello F, Schmidt-Erfurth U, Lang GE, Massin P, Schlingemann RO et al. The RESTORE study: Ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 2011; 118(4): 615-625
11. Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L et al. Ranibizumab for diabetic macular edema: Results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology 2012; 119(4): 789-801
12. Paccola L, Costa RA, Folgosa MS, Barbosa JC, Scott IU, Jorge R. Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular oedema (IBEME study Br J Ophthalmol 2008; 92(1): 76-80
13. Shahin MM, El-Lakkany RS. A prospective, randomized comparison of intravitreal triamcinolone acetonide versus intravitreal bevacizumab (avastin) in diffuse diabetic macular edema. Middle East Afr J Ophthalmol 2010; 17(3): 250-253
14. Wu L, Arevalo JF, Berrocal MH, Maia M, Roca JA, Morales-Cantón V et al. Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to branch retinal vein occlusions: Results of the Pan American Collaborative Retina Study Group at 24 months. Retina 2009; 29(10): 1396-1403
15. Ruiz-Moreno JM, Montero JA, Bayon A, Rueda J, Vidal M. Retinal toxicity of intravitreal triamcinolone acetonide at high doses in the rabbit. Exp Eye Res 2007; 84(2): 342-348
16. Chan A, Leung LS, Blumenkranz MS. Critical appraisal of the clinical utility of the dexamethasone intravitreal implant (Ozurdex) for the treatment of macular edema related to branch retinal vein occlusion or central retinal vein occlusion. Clin Ophthalmol 2011; 5: 1043-1049
17. Matsuyama K, Ogata N, MatsuokaM,Wada M, Takahashi K, Nishimura T. Plasma levels of vascular endothelial growth factor and pigment epithelium-derived factor before and after intravitreal injection of bevacizumab. Br J Ophthalmol 2010; 94(9): 1215-1218
18. Curtis LH, Hammill BG, Schulman KA, Cousins SW. Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. Arch Ophthalmol 2010; 128(10): 1273-1279
19. Sacu S, Pemp B,WeigertG, Matt G, Garhofer G, PruenteCet al. Response of retinal vessels and retrobulbar hemodynamics to intravitreal anti-VEGF treatment in eyes with branch retinal vein occlusion. Invest Ophthalmol Visual Sci 2011; 52(6): 3046-3050